{"Clinical Trial ID": "NCT00193050", "Intervention": ["INTERVENTION 1:", "Intervention", "In the neoadjuvant setting, patients received gemcitabine (800 mg/m2 IV days 1 and 8), epirubin (75 mg/m2 IV days 1) and docetaxel (30 mg/m2 IV days 1 and 8) again every 21 days for 4 cycles.", "The patients then had breast mastectomy or conservation surgery and the responses to pathological treatment were evaluated.", "After surgery, 4 cycles of adjuvant gemcitabine (1000 mg/m2 IV days 1 and 8) and docetaxel (35 mg/m2 IV days 1 and 8) were administered at 21-day intervals.", "Upon completion of chemotherapy, local regional radiotherapy and/or estrogen therapy were administered according to standard guidelines."], "Eligibility": ["Incorporation criteria:", "To be included in this study, you must meet the following criteria:", "Adenocarcinoma of the breast confirmed by biopsy", "Women Patients > 18 years of age", "Normal heart function", "\u2022 Ability to carry out activities of daily life with minimum assistance", "- Chemotherapy na\u00efve or who received prior chemotherapy > 5 years ago", "\u2022 Sensitivity of bone marrow, liver and kidneys", "To be informed of the experimental nature of this study", "Sign an Informed Consent Form", "A sentinel lymph nodes and/or axillary dissection prior to registration", "- Exclusion criteria:", "You may not participate in this study if any of the following applies to you:", "Life expectancy < 6 months", "\u2022 History of major heart disease", "\u2022 Prior chemotherapy or hormonal treatment", "Concomitant treatment with Trastuzumab", "\u2022 History of major psychiatric disorders", "\u2022 History of uncontrolled active infection", "Note: There are other inclusion and exclusion criteria. The study centre will determine if you meet all the criteria. If you are not eligible for the trial, the study staff will explain the reasons. If you are eligible, the study staff will explain the trial in detail and answer any questions you may have."], "Results": ["Performance measures:", "Complete pathological response (CPR)", "For the purposes of this study, a complete pathological response (CPR) was not defined as a residual invasive tumour in the breast (Tp0). Ductal carcinoma or residual lobular in situ was not considered in the SPC assessments.", "Time limit: 18 months", "Results 1:", "Title of the arm/group: Intervention", "In the neoadjuvant setting, patients received gemcitabine (800 mg/m2 IV days 1 and 8), epirubinin (75 mg/m2 IV days 1) and docetaxel (30 mg/m2 IV days 1 and 8) for 21 days for 4 cycles", "The patients then had breast mastectomy or conservation surgery and the responses to pathological treatment were evaluated.", "After surgery, 4 cycles of adjuvant gemcitabine (1000 mg/m2 IV days 1 and 8) and docetaxel (35 mg/m2 IV days 1 and 8) were administered at 21-day intervals.", "Upon completion of chemotherapy, local regional radiotherapy and/or estrogen therapy were administered according to standard guidelines.", "Total number of participants analysed: 110", "Type of measurement: Number", "Unit of measure: percentage of participants 18 (11-26)"], "Adverse Events": ["Undesirable Events 1:", "Total: 17/110 (15.45%)", "Hemoglobin [1]1/110 (0.91%)", "Esophagitis 1/110 (0.91%)", "Dysphagia 1/110 (0.91%)", "- Nausea/vomit 1/110 (0.91%)", "Nausea 1/110 (0.91%)", "Fever 1/110 (0.91%)", "Febrile Neutropenia 11/110 (10.00%)", "Infection - Other [2]1/110 (0.91%)", "Infection - Pneumonia 1/110 (0.91%)", "Dyspnoea 2/110 (1.82%)", "Hypoxia 1/110 (0.91%)"]}